Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Heterogeneous components of lung adenocarcinomas confer distinct EGFR mutation and PD-L1 expression

Fig. 3

a-d Kaplan–Meier curve for progression-free survival (PFS) and PD-L1 expression TPS in LACs. a The median PFS survivals were compared in different PD-L1 TPS levels and the median PFS of group PD-L1 TPS < 1% was significantly longer than that of PD-L1 > =50% (P < 0.05). b The median PFS of groups PD-L1 TPS < 1, 1–49%, > = 50% in LACs with uniformed component was 22.9 months (95% CI 11.4–34.4), 27.6 months (95% CI 18.6–36.6) and 9.8 months (95% CI 0.3–22.5), respectively (P > 0.05). c The median PFS of groups PD-L1 TPS < 1, 1–49%, > = 50% in LACs with two components. PFS of group PD-L1 TPS < 1% was 25.5 months (95% CI 18.4–32.6), compared to that of group PD-L1 TPS > =50% with PFS of 13.6 months (95% CI 10.4–16.8 (P < 0.05). d The median PFS of groups PD-L1 TPS < 1, 1–49% and > =50% in LACs with more than two histological components. No significant difference was found in these three groups

Back to article page